FDA Publishes Notice of Patent Infringement Complaint Filed Against Biosimilar Applicant

Summary

The FDA has published a notice that a biosimilar applicant has filed a patent infringement complaint, as required under the Public Health Service Act, and must provide the HHS Secretary with notice within 30 days.